Lynden International selects Cryoport as preferred cryogenic logistics provider

Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that it has been selected by Lynden International ("Lynden") as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa.

Cryoport's comprehensive cryogenic logistics solutions will complement Lynden's cold chain capabilities in support of its shipments of temperature sensitive materials for ongoing clinical trials in Africa. Cryoport's solutions ensure that the integrity of shipments and content are maintained and enable more efficient results through greater safety and speed of delivery. Cryoport's global network allows shipments to securely reach remote locations that are part of this clinical trial.

Lynden International is a full-service domestic and international freight forwarder with over 50 offices worldwide, including the United States, Micronesia, Canada, Mexico, Brazil, Russia and the Russian Far East. Lynden serves as a trusted partner to a wide variety of companies in varying industries including healthcare and pharmaceuticals.

Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "We are pleased with the opportunity to expand Lynden's capabilities with our validated cryogenic logistics solutions. We have great experience in clinical trial logistics and look forward to working with Lynden in furthering clinical trial work in Africa for underrepresented diseases. Our best-in-class cryogenic logistics solutions are a key component to providing the worldwide access that is required by the life science industry to successfully conduct clinical trials around the globe."

SOURCE Cryoport, Inc.